natgillin/translations-raw huggingface dataset:
Rostafuroxin for use in treatment or prevention of a cardiovascular condition in an individual wherein said individual has been selected to be a carrier of: at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs246191 1, rs5013093, and rs12513375 in, respectively, the nucleotide sequences of SEQ ID NO: 11, SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 5, SEQ ID NO:3 and SEQ ID NO: 7, and wherein at least one genotype is selected from the group consisting of: genotype TT for rs2345088, heterozygous genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs246191 1, genotype TT for rs5013093, and genotype TT for rs12513375 . 
Rostafuroksin za uporabu za liječenje ili sprječavanje kardiovaskularnog stanja kod pojedinca naznačen time da je navedeni pojedinac odabran da bude nositelj: barem jednog polimorfizma odabranog iz skupine koja sadrži rs2345088, rs16877182, rs16893522, rs246191 1, rs5013093, i rs12513375 u, redom, nukleotidnim sekvencama SEQ ID NO: 11, SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 5, SEQ ID NO:3 i SEQ ID NO: 7, te pri čemu je barem jedan genotip odabran iz skupine koja sadrži: genotip TT za rs2345088, heterozigotni genotip C/T za rs16877182, genotip AA za rs16893522, genotip AA za rs246191 1, genotip TT za rs5013093, te genotip TT za rs12513375 .
The compound or composition for use according to claim 1, wherein the disease or disorder is hematologic cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
pp. 005-C04-8-2 comprises a variable heavy chain domain corresponding to a nucleic acid sequence according to SEQ ID NO: 415, and an amino acid sequence according to SEQ ID NO: 227, and a variable light chain domain with a nucleic acid sequence according to SEQ ID NO: 487, and an amino acid sequence according to SEQ ID NO: 299, 
-H08-68-35-2 sadrži promjenjivu domenu teškog lanca koja odgovara sekvenci nukleinske kiseline u skladu sa SEQ ID NO: 352, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 164, i promjenjivu domenu lakog lanca sa sekvencom nukleinske kiseline u skladu sa SEQ ID NO: 374, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 186.
According to one embodiment the first pattern and the second pattern overlap by at least 50%, preferably at least 75%, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 99%. 
Postupak prema zahtjevu 1, naznačen time da se prvi uzorak i drugi uzorak preklapaju za barem 50 %, poželjno barem 75 %, poželjnije barem 90 %, još poželjnije barem 95 %, i najpoželjnije barem 99 %.
A compound of formula I according to claim 1, wherein Y represents a group of formula 
Spoj formule I prema zahtjevu 1, naznačen time, da Y predstavlja skupina formula bo
Medium number of Nosema apis spores 
(21) Broj predmeta:
TiO2 in an amount of from 0 to 3 wt%, 
TiO> u količini od 0 do 3 tež.%,
A compound according to claim 5, characterized by an X ray diffraction pattern essentially as defined in Figure 3 and/or in Table 3: 
6. Spoj prema zahtjevu 5, naznačen time da je uzorak difrakcije X-zraka u osnovi kako je definirano na slici 3 iili u Tabeli 3:
The compound for the use of claim 5, wherein said method comprises administering to the subject a composition comprising an excipient and a therapeutically effective amount of a compound of claim 1, or a therapeutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 9, naznačen time što navedeni postupak obuhvaća davanje subjektu pripravka koji sadrži pomoćnu tvar i terapeutski učinkovitu količinu spoja prema zahtjevu 1, ili njegove terapeutski prihvatljive soli.
In one embodiment, RC is a linker group RL lacking the functional group for connection to the cell binding agent. 
A je spojna skupina koja spaja L' na sredstvo za vezanje stanice (CBA);
the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:69, a CDR2 region of SEQ ID NO: 70, and a CDR1 region of SEQ ID NO:71, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 72, a CDR2 region of SEQ ID NO:73, and a CDR1 region of SEQ ID NO:74, or 
varijabilna domena jakog lanca obuhvaća područje CDR3 od SEQ ID NO:25, područje CDR2 od SEQ ID NO:26, i područje CDR1 od SEQ ID NO:27, te varijabilna domena slabog lanca obuhvaća područje CDR3 od SEQ ID NO:28, područje CDR2 od SEQ ID NO:29, i područje CDR1 od SEQ ID NO:30, ili
and R2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms, 
može biti alkil-skupina koja ima od 1 do 5 atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od 1 do 5 atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od 1 do 3 atoma ugljika,
A compound of formula (Ie) according to claims 1, 2, 3 and 10, wherein R2 is a hydrogen atom; R3 is a 4-pyridyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a -NH-(CH2)a-NR6R7 group, a being an integer 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; 
Spoj s formulom (Ie) prema zahtjevima 1, 2, 3, 4 i 10, naznačen time da R2 je vodikov atom; R3 je skupina 4-piridil; R4 je karbonilna skupina ili sulfonilna skupina; i je -NH-(CH2)a-NR6R7 skupina, a je cijeli broj 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je odabrana između skupine 4-metilpiperazinil, morfolino skupine, pirolidinil skupine i piperidino skupine;
A derivative for use according to claim 1 wherein G1 is optionally substituted aryl C1-C6 alkyl and optionally substituted heteroaryl C1-C6 alkyl. 
Derivat za upotrebu prema patentnom zahtjevu 1, naznačen time da G1 predstavlja opcionalno supstituiranog aril C1-C6 alkila i opcionalno supstituiranog heteroaril C1-C6 alkila.
heating said preform to blow-moulding temperature in a single oven; and blow-moulding the thus heated preform to form a bag-in-container; characterized in that the type and amount of additives in at least one of the inner and outer layers of said preform are such that said two layers reach their respective blow-moulding temperatures substantially simultaneously in said single infrared oven. 
- < oblikovanje u kalupu puhanjem tako zagrijanog predsklopa za formiranje posude s vrećicom u njoj; naznačen time da su vrsta i količina aditiva u barem jednom od unutamjeg i vanjskog sloja spomenutog predsklopa takvi da spomenuta dva sloja svoju, odgovarajuću temperaturu oblikovanja u kalupu puhanjem dostižu u osnovi istovremeno spomenutoj infracrvenoj peći.
Catalogue number: 101254H). 
(86) Broj međunarodne prijave:
a light chain comprising (i) a variable light (VL) domain comprising a CDR1 polypeptide consisting of the amino acid sequence of SEQ ID NO:4, a CDR2 polypeptide consisting of the amino acid sequence of SEQ ID NO:5, and CDR3 polypeptide consisting of the amino acid sequence of SEQ ID NO:6, and (ii) a constant light (CL) domain comprising a polypeptide consisting of the amino acid sequence of SEQ ID NO:586; and 
laki lanac koji obuhvaća (i) varijabilnu laku (VL) domenu koji ima CDR1 polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:4, CDR2 polipeptida koji se sastoji od aminokiselinskog slijeda SEQ ID NO:5, i CDR3 polipeptida koji se sastoji od aminokiselinskog slijeda SEQ ID NO:6, i (ii) konstantnu laku (CL) domenu koja ima polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:586; i
The pharmaceutical composition according to claim 1 or claim 2 wherein the prilocaine HCl content is 2% (w/V). 
Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2, naznačena time što je sadržaj prilokaina HCI 2% (tež./vol.).
The recombinant prokaryotic biosynthetic system of claim 3, wherein said oligo- or polysaccharide is from Shigella flexneri, preferably from Shigella flexneri 6; or E . coli preferably E coli 0157. 
Rekombinantni prokariotski biosintetski sustav u skladu s patentnim zahtjevom 3, naznačen time što je navedeni oligo- ili polisaharid iz bakterije Shigella flexneri, po mogućnosti iz bakterije Shigella flexneri 6; ili E. coli po mogućnosti € coli 0157.
LDL at a final protein concentration of 0.2 mg/ml was incubated in the presence of 2.5 um haemin and 5 um H2O2. 
LDL pri krajnjoj koncentraciji proteina od 0,2 mg/ml inkubiran je u HR P20090152 T3 prisutnosti 2,5 uM hemina i 5 uM H,O,.
is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group; 
je odabran iz skupine koja sadrži vodik i metil;
% Bi2O3 are mechanically homogenized and pelletized with pressure of 255 MPa, and after that crushed to grading of grain size of 0.2 - 0.8 mm. 
% Bi2O3 mehanički homogenizirane i granulirane pod tlakom od 255 MPa, a nakon čega se drobe do veličine zrna od 0.2 – 0.8 mm.
Optionally, also the combination hot water and steam can be provided. 
Izborno se može dobiti i kombinacija vruće vode i vodene pare.
Process step c) according to claim 12 for the manufacture of compounds of general formula I, characterized in that ketones of type (IX) optionally in its enantiomerically pure form can be condensed with substituted amino quinolones of type (III) to imines and subsequently or simultaneously reduced to yield compounds formula I wherein R1, R2, R3, R4 and R5 have the meanings that are indicated in claim 1 and R as defined in claim 8 and optionally subsequently a separation of diastereoisomers may be performed. 
13. Korak c) postupka prema zahtjevu 12 koji je za proizvodnju spojeva opće formule I, naznačen time da ketoni vrste (IX) proizvoljno u njihovom enantiomerno čistom obliku mogu biti kondenzirani sa supstituiranim amino kinolonima vrste (III) u imine i naknadno ili istovremeno mogu biti reducirani da se dobiju spojevi formule I hi, <a a
the composition further comprises optionally an amount of about 2 mg of EDTA, and the composition being reconstituted with about 20 ml of water for injection. In this composition the total amount of sodium content of the ceftriaxone sodium and the sulbactam sodium is about 264.6 mg with 11.48 mEq of sodium. 
(c) EDTA u količini od 2 mg, spomenuta smjesa je rekonstituirana sa 20 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 264,6 mg, uz 11.48 mEq natrija.
exposing one or more compounds of interest to an antibody of any one of claims 1-4, or 6 for a time and under conditions sufficient for said one or more compounds to bind to said antibody of any one of claims 1-4, or 6; and identifying those compounds which bind to said antibody of any one of claims 1-4, or 6, said identified compounds to be used in active immunization in a patient predicted to develop Alzheimer's Disease. 
Alzheimerovu bolest koja uključuje korake: a) izlaganja jednog ili više spojeva koji su od interesa antitijelu temeljem bilo kojeg od zahtjeva 1-4, ili 6 kroz vrijeme i pod uvjetima dostatnima da se navedeni jedan ili više spojeva spoje sa navedenim antitijelom temeljem bilo kojeg od zahtjeva 1-4, ili 6; i b) identificiranje onih spojeva koji se vezuju za navedeno antitijelo temeljem bilo kojeg od prethodnih zahtjeva 14, ili 6, a navedeni spojevi su namijenjeni korištenju kod aktivne aimunizacije kod pacijenata za koje se predviđa da će razviti Alzheimerovu bolest.
The container 1100 also includes a plurality of locking members 1104 that are positioned about the periphery of the container 1100. 
Posuda 1100 također uključuje više dijelova za pričvršćivanje 1104 koji se nalaze oko ruba posude 1100.
Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, n -propyl, n-butyl, C1-4 alkoxy and C3-5 cycloalkyl; or 
Prsten A je supstituiran s 1 ili 2 supstituenda izabrana iz skupine koju čine: halogen, n-propil, n-butil, C,.4 alkoksi, te
The compound for use according to claim 1, wherein said compound has formula (VI): wherein 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VI):
The composition of Claim 25, wherein a second therapeutic agent is present and is selected from anti-Alzheimer's agents, anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof. 
Farmaceutski pripravak sukladno patentnom zahtjevu 6, naznačen time, da dodatno sadrži sekundarno terapijsko sredstvo odabrano između sredstava protiv Alzheimerove bolesti, antikonvulzanata, antidepresiva, sredstava protiv Parkinsonove bolesti, dualnih inhibitora ponovnog preuzimanja serotonin-norepinefrina, ne-steroidnih protuupalnih sredstava, inhibitora ponovnog preuzimanja norepinefrina, opioidnih agonista, opioidnih antagonista, selektivnih inhibitora ponovnog preuzimanja serotonina, blokatora kalijevih kanala, simpatolitika i njihove kombinacije.
Hence, the sIL-6R has the ability to widen the repertoire of cell types that are responsible to IL-6. 
Dakle, sIL- 6R ima sposobnost da proširi repertoar stanica koje odgovaraju na IL-6.
Typically, the IL-2 will not be mixed with the other active ingredient before administration; rather, the IL-2 and the other active ingredient will be administered as separate independent medicines in a combined protocol. 
Tipično, IL-2 se neće miješati s drugim aktivnim sastojkom prije davanja; štoviše, IL-2 i drugi aktivni sastojak će se davati kao poseban nezavisni lijek u kombiniranom protokolu.
The method of claim 42, wherein said synthetic substance, after the chemical reaction for expansion and setting, in confinement conditions occurring during use, has a modulus of elasticity ranging from 10 MPa to 50 MPa for densities ranging from 50 kg/m3 to 200 kg/m3. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da spomenuta sintetička tvar (4), nakon kemijske reakcije proširenja i postavljanja, u ograničenim uvjetima koji se javljaju prilikom uporabe, ima modul elastičnosti u rasponu uglavnom od 10 MPa do 50 MPa za gustoće u rasponu uglavnom od 50 kg/m*do 200 kg/m.
Even when the starting material was taken from the same batch of the monoclinic form of asenapine maleate, micronization resulted in product that was not reproducible (see examples 9 and 10). 
Čak i kad je početni materijal uzet iz dobivene količine monoklinskog oblika asenapin maleata, mikronizacija bi rezultirala produktom koji nije bilo moguće ponoviti (vidi primjere 9 i 10).
The combination of Claim 8, wherein the B-lactamase inhibitor is in the form of a sodium or calcium salt. 
Kombinacija sukladno patentnom zahtjevu 8, naznačena time što je f-laktamazni inhibitor u obliku natrijeve ili kalcijeve soli.
The dry sinsemilla cannabis inflorescence of claim 1 or claim 2, wherein the first or second most abundant terpene in the terpene profile is selected from the group consisting of terpinolene, alpha pinene, limonene, and beta caryophyllene. 
Suha inflorescencija besjemenog kanabisa u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što se prvi ili drugi najobilatiji terpen u terpenskom profilu bira iz skupine koju čine terpinolen, a-pinen, limonen, te B-kariofilen.
The pharmaceutical formulation according to claims 1 or 2, further including a tensioactive component compatible with the soluble amphiphilic matrix and/or dispersible homogeneously in the amphiphilic matrix. 
Farmaceutska formulacija u skladu s patentnim zahtjevima 1 ili 2, naznačena time što dodatno sadrži tenzioaktivnu komponentu koja je kompatibilna s topljivim amfifilnim matriksom i/ili se može homogeno dispergirati u amfifilnom matriksu.
wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups. 
Formula lil pri čemu Y je druga reaktivna skupina, n je odabran od cijelih brojeva u rasponu od 1 do 10, i P je odabran od amino zaštitnih skupina.
This result further demonstrates the potential of the rapamycin carbohydrate derivatives of the present invention to improve the pharmacodynamic profile of rapamycin. 
Taj razultat dodatno pokazuje potencijal ugljikohidratnih derivata rapamicina ovog izuma na poboljšanje farmakodinamskog profila rapamicina.
0.05-1.2%; wherein a total weight percentage of the above components is greater than or equal to 98%; and 
(nastavak) pri čemu je raspon kombiniranog postotka mase gore navedenih komponenata najmanje 98%, a raspon omjera težine u postotku C1= Al2O3 / SiO2je 0.294-0.346.
The optical navigation system of any preceding claim, wherein at least one of the markers comprises a characteristic feature, the characteristic feature being any one or more of the group comprising: the marker being of a particular shape; the marker comprising a barcode; and the marker being automatically identifiable by a machine vision system. 
Sustav za optičku navigaciju (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje jedna od oznaka (26) sadrži karakteristično obilježje, gdje je karakteristično obilježje bilo koje od ili više toga iz skupine koju čine: oznaka određenog oblika; oznaka koja sadrži barkod; te oznaka koju automatski prepoznaje sustav za strojno gledanje.
In one embodiment, the ring 1103 is a generally cylindrical wall having an outer surface and inner surface. 
U jednom ostvarenju, obruč 1103 je obično cilindrična stijenka s vanjskom i unutarnjom površinom.
controlling the concentration of zinc in the culture medium, thereby producing the antibody or antigen-binding fragment thereof. The method of claim 1, wherein: the C-terminal lysine content of the antibody is 40% to 70%, optionally 55% to 65%, and optionally 60%; and/or 
Postupak prema zahtjevu 1, naznačen time što: a) sadržaj C-terminalnog lizina protutijela je 40% do 70%, proizvoljno 55% do 65%, i proizvoljno 60%; i/ili b) sadržaj sijalinske kiseline protutijela je 3% do 14%.
A combination according to claim 4 wherein the anti-inflammatory agent is a corticosteroid or an NSAID. 
Kombinacija u skladu s patentnim zahtjevom 5, naznačen time što je protuupalno sredstvo kortikosteroid.
at least one inclined support rod of the cross-member having one side attached to the pylon or post and the other attached to the cross-member, near to a free end of the cross-member; 
- = barem jednu zakošenu potpornu šipku (100) tog poprečnog elementa (8) čija je jedna strana pričvršćena na pilon ili stup (160) dok je druga pričvršćena na taj poprečni element, u blizini slobodnog kraja dotičnoj poprečnog elementa; i
the variable heavy chain comprises the variable heavy chain framework sequence from IGHV1-f and the CDRs from the VH chain of murine antibody HP1/2, wherein CDR1 comprises the sequence GFNIKDTYM, CDR2 comprises the sequence RIDPASGDTKYDPKFQV and CDR3 comprises the sequence GMWVSTGYALDF; and, 
(a) varijabilni jaki lanac obuhvaća okvirnu sekvencu varijabilnog jakog lanca od IGHVI-f i CDR-ove od VH- lanca mišjeg protutijela HP1/2, gdje CDR1 obuhvaća sekvencu GFNIKDTYM, CDR2 obuhvaća sekvencu RIDPASGDTKYDPKFQV 1 CDR3 obuhvaća sekvencu GMWVSTGYALDF; 1
wherein the meaning of R1 and X is as described above for the formula (I), and an amine of formula (III): 
(IV) gdje je značenje od R, 1 X kao što je gore opisano za formulu (I), i amina formule (III):
Cells are capable of adhering and propagating on the surface of microcarriers. 
Stanice su sposobne za pričvršćivanje i rast na površini mikronosača.
A speech decoding device 24m (see FIG 42) of a modification 14 of the embodiment physically includes a CPU, a ROM, a RAM, a communication device, and the like, which are not illustrated, and the CPU integrally controls the speech decoding device 24m by loading and executing a predetermined computer program (such as a computer program for performing processes illustrated in the flowchart of FIG 43) stored in a built-in memory of the speech decoding device 24m such as the ROM into the RAM. The communication device of the speech decoding device 24m receives the encoded multiplexed bit stream and outputs a decoded speech signal to outside the speech decoding device 24m. 
Postupak dekodiranja govora u kojem se upotrebljava naprava za dekodiranje govora za dekodiranje kodiranog govornog signala, naznačen time što se postupak dekodiranja govora sastoji u: koraku osnovnog dekodiranja, u kojem naprava za dekodiranje govora dekodira struju bitova koja sadrži kodirani govorni signal kako bi se dobilo niskofrekventnu komponentu, gdje struja bitova dolazi izvan naprave za dekodiranje govora; koraku pretvorbe frekvencije, u kojem naprava za dekodiranje govora pretvara niskofrekventnu komponentu dobivenu u koraku osnovnog dekodiranja u frekventno područje;
Netupitant for use according to claims 1-3, wherein a therapeutically effective amount of a 5-HT3 antagonist is further administered. 
Farmaceutski pripravak prema patentnim zahtjevima 1-3, naznačen time što navedena terapeutski efikasna količina netupitanta sadrži oko 300 mg netupitanta kao slobodna baza.
The bispecific single chain antibody of claim 1, wherein said second binding domain specific for human CEA comprises at least the amino acid sequence "DRGLRFYFDY" (SEQ ID NO. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedena druga vežuća domena specifična za ljudski CEA u najmanju ruku sadrži aminokiselinski slijed "DRGLRFYFDY" (SEQ ID NO.
The compound for use according to claim 1, wherein the ALK- or FAK-mediated condition or disorder is a FAK-mediated condition or disorder. 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu ALK- ili FAK- posredovano stanje ili poremećaj je FAK-posredovano stanje ili poremećaj.
The composition of claim 7, wherein said regulatory RNA targets the transcript encoding a protein that contributes to resistance to said drug. 
Pripravak prema zahtjevu 7, gdje ta regulatorna RNA cilja transkripciju koja kodira protein koji doprinosi otpornosti na taj lijek.
A clip (7) as claimed in claim 20, wherein the bend is approximately 65°. 
Držač (7) u skladu s patentnim zahtjevom 20, kod kojega je savijeni dio savijen pod kutom od približno 65".
The samples were prepared by 1:1 (v/v) dilution of the fermented decolourised caramel with acetonitrile followed by filtration (PVDF 0.45 µM syringe filters) prior to analysis. 
Uzorci su pripremljeni 1:1 (v/v) razrjeđivanjem fermentirane obezbojene karamele s acetonitrilom, nakon čega je slijedila filtracija (PVDF 0,45 uM filtri šprica) prije analize.
a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 39 and a light chain sequence comprising amino acid sequence SEQ ID NO: 40, or 
Protutijelo protiv HIV-a, naznačeno time što je navedeno protutijelo PG9, koji ima teški lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 39, i laki lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 40.
The pharmaceutical composition for use according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da daje stacionarno stanje razine u plazmi 30a-hidroksi-3-metoksimetil-2 1-(1*-imidazolil)-5a-pregnan-20-ona u rasponu od 50 ng/ml to 250 ng/ml.
exhibits reduced antibody-dependent-cellular cytotoxicity (ADCC) compared to an antibody comprising a wild-type Fc domain, as measured in an in vitro cytotoxicity assay; 
ispoljava smanjenju staničnu citotoksičnost ovisnu o antitijelu (engl. antibody-dependent-celllular cytotoxicity, ADCC) u usporedbi s antitijelom koje sadrži Fc domenu divljeg tipa, kada se mjeri in vitro testom citotoksičnosti;
The process according to claim 1, wherein the liquid composition step a) and in step b) is an aqueous solution. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6 pri čemu je tekući sastav u koraku a) i u koraku b) vodena otopina.